NANS24: Boston Scientific Reports Positive WaveWriter SCS Data

Boston Scientific presented one-year results from its SOLIS trial that showed sustained pain relief using the WaveWriter Alpha spinal cord stimulation (SCS) systems to treat non-surgical back pain (NSBP). The data was presented at this year’s North American Neuromodulation Society (NANS) meeting.
 
90% of patients treated with the WaveWriter systems at the primary endpoint interval reported significant pain relief of 50% or more without an opioid increase, compared to 8% of patients treated with conventional medical management (CMM) alone. At one year, 84% of patients treated with WaveWriter reported significant pain relief of 50% or more, as well as sustained improvement in the ability to participate in daily living activities.
 
CMM patients who chose to receive SCS therapy also had significant pain and disability improvement at one year—85% of crossover subjects reported 50% or more pain reduction.
 
“Continued positive results from the SOLIS study illustrate the need for early and effective pain treatment when just the standard of care is not enough,” said Jim Cassidy, president, Neuromodulation, Boston Scientific. “Backed by consistently strong clinical evidence, our transformative pain management solutions help individualize care and improve the quality of life for the many people living with chronic pain today.”
 

SCS for Painful Diabetic Peripheral Neuropathy (DPN)

Boston Scientific presented real-world outcomes for long-term time points using SCS therapy for patients with DPN.
 
At the two-year follow-up, 81% of patients reported 50% or greater pain reduction. A high level of improvement and treatment satisfaction was also reported at an up to three-year follow-up.
 

Outcomes Using FAST (Fast-Acting Sub-Perception-Based) Therapy

Boston Scientific also presented data from multiple prospective and real-world studies from Europe and the U.S. about its FAST Therapy.
 
FAST Therapy was designed to offer immediate, paresthesia-free relief. At one-year follow-up, at least 88% of SCS patients reported 50% or more pain relief. Evaluation of 311 enrolled patients is ongoing.
 
Learn more about SCS and other device-based treatments for chronic pain here!